Onconetix和Ocuvex Therapeutics宣布合并协议; Onconetix将收购Ocuvex的所有已发行和未发行股权，Ocuvex股权持有者将获得Onconetix普通股，相当于合并后公司已发行和未发行股权的90%。

Pursuant to the Merger Agreement, Onconetix will acquire all of the issued and outstanding equity interests of Ocuvex and, in consideration for their equity interests, Ocuvex equity holders will receive newly-issued shares of Onconetix common stock equal to 90% of the issued and outstanding equity interests in the combined company as of immediately following the closing of the Proposed Transaction, on a fully diluted basis, subject to adjustment due to any transaction-related equity financing. Onconetix shareholders will retain 10% of the issued and outstanding equity interests in the combined company on a fully diluted basis as of immediately following the Proposed Transaction.